Suppr超能文献

基于 RISC 的 RNA 测序技术实现体内 microRNA 靶基因的特定条件识别。

RISC RNA sequencing for context-specific identification of in vivo microRNA targets.

机构信息

Center for Pharmacogenomics, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.

出版信息

Circ Res. 2011 Jan 7;108(1):18-26. doi: 10.1161/CIRCRESAHA.110.233528. Epub 2010 Oct 28.

Abstract

RATIONALE

MicroRNAs (miRs) are expanding our understanding of cardiac disease and have the potential to transform cardiovascular therapeutics. One miR can target hundreds of individual mRNAs, but existing methodologies are not sufficient to accurately and comprehensively identify these mRNA targets in vivo.

OBJECTIVE

To develop methods permitting identification of in vivo miR targets in an unbiased manner, using massively parallel sequencing of mouse cardiac transcriptomes in combination with sequencing of mRNA associated with mouse cardiac RNA-induced silencing complexes (RISCs).

METHODS AND RESULTS

We optimized techniques for expression profiling small amounts of RNA without introducing amplification bias and applied this to anti-Argonaute 2 immunoprecipitated RISCs (RISC-Seq) from mouse hearts. By comparing RNA-sequencing results of cardiac RISC and transcriptome from the same individual hearts, we defined 1645 mRNAs consistently targeted to mouse cardiac RISCs. We used this approach in hearts overexpressing miRs from Myh6 promoter-driven precursors (programmed RISC-Seq) to identify 209 in vivo targets of miR-133a and 81 in vivo targets of miR-499. Consistent with the fact that miR-133a and miR-499 have widely differing "seed" sequences and belong to different miR families, only 6 targets were common to miR-133a- and miR-499-programmed hearts.

CONCLUSIONS

RISC-sequencing is a highly sensitive method for general RISC profiling and individual miR target identification in biological context and is applicable to any tissue and any disease state.

摘要

背景

MicroRNAs(miRs)正在扩展我们对心脏疾病的认识,并有可能改变心血管治疗学。一个 miR 可以靶向数百个单独的 mRNA,但现有的方法学不足以准确和全面地在体内鉴定这些 mRNA 靶标。

目的

开发允许以无偏倚的方式鉴定体内 miR 靶标的方法,方法是结合对与小鼠心脏 RNA 诱导沉默复合物(RISCs)相关的 mRNA 的测序,对小鼠心脏转录组进行大规模平行测序。

方法和结果

我们优化了在不引入扩增偏差的情况下对少量 RNA 进行表达谱分析的技术,并将其应用于从小鼠心脏中抗 Argonaute 2 免疫沉淀的 RISCs(RISC-Seq)。通过比较来自同一个体心脏的心脏 RISC 和转录组的 RNA 测序结果,我们确定了 1645 个一致靶向小鼠心脏 RISCs 的 mRNA。我们在过表达来自 Myh6 启动子驱动前体的 miR 的心脏中使用这种方法(编程的 RISC-Seq),鉴定了 miR-133a 的 209 个体内靶标和 miR-499 的 81 个体内靶标。与 miR-133a 和 miR-499 具有广泛不同的“种子”序列并属于不同的 miR 家族的事实一致,只有 6 个靶标是 miR-133a 和 miR-499 编程心脏共有的。

结论

RISC-seq 是一种高度敏感的方法,可用于在生物学背景下进行一般 RISC 分析和单个 miR 靶标鉴定,适用于任何组织和任何疾病状态。

相似文献

7
Regulation of cardiac microRNAs by cardiac microRNAs.心脏 microRNAs 对心脏 microRNAs 的调控。
Circ Res. 2013 Jun 21;113(1):62-71. doi: 10.1161/CIRCRESAHA.113.300975. Epub 2013 Apr 26.
10
siRNA and miRNA: an insight into RISCs.小干扰RNA和微小RNA:对RNA诱导沉默复合体的深入了解
Trends Biochem Sci. 2005 Feb;30(2):106-14. doi: 10.1016/j.tibs.2004.12.007.

引用本文的文献

1
Technologies to Study Genetics and Molecular Pathways.研究遗传学和分子途径的技术。
Adv Exp Med Biol. 2024;1441:435-458. doi: 10.1007/978-3-031-44087-8_22.
5
Exosomal microRNAs in diabetic heart disease.糖尿病性心脏病中的细胞外体 microRNAs。
Cardiovasc Diabetol. 2022 Jul 1;21(1):122. doi: 10.1186/s12933-022-01544-2.

本文引用的文献

2
MicroRNA regulatory networks in cardiovascular development.心血管发育中的 microRNA 调控网络。
Dev Cell. 2010 Apr 20;18(4):510-25. doi: 10.1016/j.devcel.2010.03.010.
5
MiR423-5p as a circulating biomarker for heart failure.miR423-5p 作为心力衰竭的循环生物标志物。
Circ Res. 2010 Apr 2;106(6):1035-9. doi: 10.1161/CIRCRESAHA.110.218297. Epub 2010 Feb 25.
6
microRNAs in heart disease: putative novel therapeutic targets?心脏病中的微小RNA:潜在的新型治疗靶点?
Eur Heart J. 2010 Mar;31(6):649-58. doi: 10.1093/eurheartj/ehp573. Epub 2010 Jan 29.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验